Many will look back at these prices and seriously regret underestimating CUV.
With less than 50mil on issue (if I recall correctly) entering at $21 is an attractive prospect.
Considerably less speculative than over-hyped Aus Biotechs like MSB. And as evidenced by this announcement, with an expanding pipeline leveraging existing trial data, who knows what other indications are on the cards but the potential is clearly there.
A great company to invest for the mid-long term imo
Ann: afamelanotide for Acute Stroke Patients, page-9
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.96 |
Change
-0.210(1.48%) |
Mkt cap ! $701.3M | |||
| Open | High | Low | Value | Volume |
| $14.10 | $14.11 | $13.90 | $1.044M | 74.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1049 | $13.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 359 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |